Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances
Introduction
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 14 May 2018, the Council decided that CUMYL-4CN-BINACA should be subject to control measures across the Member States.
Download as PDF
Table of contents
- Foreword
- EMCDDA actions on monitoring and responding to new drugs
- Europol–EMCDDA Joint Report on CUMYL-4CN-BINACA (1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide) — a summary
- Risk Assessment Report on a new psychoactive substance: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
- Technical report on 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA)
- Participants of the risk assessment meeting, 7-8 November 2017
Council Implementing Decision on subjecting CUMYL-4CN-BINACA to control measures
Pages:
60
Price:
Free
ISBN:
978-92-9497-291-0
ISSN:
1725-4493
Pub. DOI:
10.2810/408735
Catalog Number:
TDAK18002ENN
Main subject